LT2702155T - Mikro rnr junginiai ir būdai mir-21 aktyvumo moduliavimui - Google Patents

Mikro rnr junginiai ir būdai mir-21 aktyvumo moduliavimui

Info

Publication number: LT2702155T
Authority: LT; Lithuania
Prior art keywords: activity; methods; modulating mir; microrna compounds; microrna
Prior art date: 2011-04-25

Application number

LTEP12718549.4T

Other languages

English (en)

Inventor

Balkrishen Bhat

Original Assignee

Regulus Therapeutics Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-04-25

Filing date

2012-04-25

Publication date

2017-05-10

2012-04-25 Application filed by Regulus Therapeutics Inc. filed Critical Regulus Therapeutics Inc.

2017-05-10 Publication of LT2702155T publication Critical patent/LT2702155T/lt

Links

150000001875 compounds Chemical class 0.000 title 1
108091062762 miR-21 stem-loop Proteins 0.000 title 1
108091041631 miR-21-1 stem-loop Proteins 0.000 title 1
108091044442 miR-21-2 stem-loop Proteins 0.000 title 1
108091070501 miRNA Proteins 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Genetics & Genomics (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Microbiology (AREA)
Oncology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Obesity (AREA)
Endocrinology (AREA)

LTEP12718549.4T 2011-04-25 2012-04-25 Mikro rnr junginiai ir būdai mir-21 aktyvumo moduliavimui LT2702155T (lt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201161478767P	2011-04-25	2011-04-25
US201161565779P	2011-12-01	2011-12-01
PCT/US2012/034880 WO2012148952A1 (en)	2011-04-25	2012-04-25	Microrna compounds and methods for modulating mir-21 activity

Publications (1)

Publication Number	Publication Date
LT2702155T true LT2702155T (lt)	2017-05-10

Family

ID=46025979

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
LTEP17153724.4T LT3211082T (lt)	2011-04-25	2012-04-25	Mikro rnr junginiai ir būdai mir-21 aktyvumui moduliuoti
LTEP12718549.4T LT2702155T (lt)	2011-04-25	2012-04-25	Mikro rnr junginiai ir būdai mir-21 aktyvumo moduliavimui

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
LTEP17153724.4T LT3211082T (lt)	2011-04-25	2012-04-25	Mikro rnr junginiai ir būdai mir-21 aktyvumui moduliuoti

Country Status (30)

Country	Link
US (7)	US9181547B2 (lt)
EP (3)	EP3211082B1 (lt)
JP (2)	JP6320292B2 (lt)
KR (2)	KR102055172B1 (lt)
CN (3)	CN103620035B (lt)
AU (4)	AU2012249851B2 (lt)
BR (1)	BR112013027187A2 (lt)
CA (2)	CA3165397A1 (lt)
CL (1)	CL2013003105A1 (lt)
CO (1)	CO6821889A2 (lt)
CY (1)	CY1120304T1 (lt)
DK (2)	DK3211082T3 (lt)
EA (1)	EA025894B1 (lt)
ES (2)	ES2621863T3 (lt)
HR (2)	HRP20170557T2 (lt)
HU (2)	HUE031595T2 (lt)
IL (3)	IL229032B (lt)
LT (2)	LT3211082T (lt)
MX (5)	MX2013012452A (lt)
MY (2)	MY175336A (lt)
NZ (1)	NZ717921A (lt)
PH (1)	PH12013502199A1 (lt)
PL (2)	PL2702155T3 (lt)
PT (2)	PT3211082T (lt)
RS (1)	RS61775B1 (lt)
SG (1)	SG194636A1 (lt)
SI (2)	SI3211082T1 (lt)
TW (2)	TWI698445B (lt)
UA (1)	UA115652C2 (lt)
WO (1)	WO2012148952A1 (lt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2857881A1 (en)	2004-11-12	2006-12-28	Asuragen, Inc.	Methods and compositions involving mirna and mirna inhibitor molecules
EP3211082B1 (en)	2011-04-25	2021-02-17	Sanofi	Microrna compounds and methods for modulating mir-21 activity
EP2836219A1 (en) *	2012-04-10	2015-02-18	INSERM - Institut National de la Santé et de la Recherche Médicale	Methods for the treatment of nonalcoholic steatohepatitis
PE20142404A1 (es)	2012-04-25	2015-02-02	Regulus Therapeutics Inc	Compuestos de microarn y metodos de modulacion de la actividad de mir-21
UA116639C2 (uk)	2012-10-09	2018-04-25	Рег'Юлес Терап'Ютікс Інк.	Способи лікування синдрому альпорта
US10077443B2 (en)	2012-11-15	2018-09-18	Roche Innovation Center Copenhagen A/S	Oligonucleotide conjugates
SG11201508925WA (en)	2013-05-01	2015-11-27	Regulus Therapeutics Inc	Microrna compounds and methods for modulating mir-122
US9994846B2 (en)	2013-10-25	2018-06-12	Regulus Therapeutics Inc.	MicroRNA compounds and methods for modulating miR-21 activity
KR101625755B1 (ko)	2013-11-18	2016-05-30	울산대학교 산학협력단	ｍｉＲＮＡ 스폰지 및 이의 용도
WO2015113922A1 (en) *	2014-01-30	2015-08-06	Roche Innovation Center Copenhagen A/S	Poly oligomer compound with biocleavable conjugates
CN105734127A (zh) *	2016-02-29	2016-07-06	上海中医药大学	miR-21-3p在制备用于检测早期急性肾损伤的试剂中的用途
US20190127736A1 (en) *	2016-04-29	2019-05-02	Aptamir Therapeutics, Inc.	Inhibition of mir-22 mirna by apt-110
EP4035659A1 (en)	2016-11-29	2022-08-03	PureTech LYT, Inc.	Exosomes for delivery of therapeutic agents
CN111386351A (zh)	2017-09-22	2020-07-07	华盛顿大学	细胞分子的原位组合标记
CN108148911B (zh) *	2018-03-02	2019-11-05	广州医科大学附属第二医院	miR-582在制备前列腺癌骨转移的诊断、预后试剂盒及药物中的应用
EP3790972A1 (en)	2018-05-08	2021-03-17	Regulus Therapeutics Inc.	Galnac conjugated modified oligonucleotide as mir-122 inhibitor having hcv antiviral activity with reduced hyperbilirubinemia side-effect
CN110747266A (zh) *	2018-07-23	2020-02-04	深圳先进技术研究院	miR-21和miR-21拮抗剂在抑制预防/治疗1型糖尿病中的应用
CN109880907A (zh) *	2019-03-26	2019-06-14	中国人民解放军第八一医院	一种肝癌细胞侵袭转移的分子机制研究方法
US11965162B2 (en)	2020-04-16	2024-04-23	The Johns Hopkins University	MicroRNA and inhibitors thereof and methods of treatment
WO2022165092A1 (en) *	2021-01-29	2022-08-04	Angion Biomedica Corp.	Methods for treatment of fibrotic diseases
WO2025110217A1 (ja) *	2023-11-22	2025-05-30	国立大学法人東海国立大学機構	嚢胞性腎疾患の予防及び／又は治療剤
CN120505413A (zh) *	2025-07-15	2025-08-19	湖南工程学院	一种基于引物交换反应和G-四链体检测AKI相关miRNA的探针体系及方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ508317A (en)	1998-05-22	2004-01-30	Boys Town Nat Res Hospital	Use of alpha1beta1 integrin receptor inhibitors and tgf-beta1 inhibitors in the treatment of kidney disease
US20060008817A1 (en) *	2000-12-08	2006-01-12	Invitrogen Corporation	Methods and compositions for generating recombinant nucleic acid molecules
EP2390331B1 (en)	2001-09-28	2018-04-25	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	MicroRNA molecules
CA2504694C (en)	2002-11-05	2013-10-01	Isis Pharmaceuticals, Inc.	Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US20050124591A1 (en)	2003-07-29	2005-06-09	Jin Tian	Use of vitamin Ds to treat kidney disease
US7683036B2 (en)	2003-07-31	2010-03-23	Regulus Therapeutics Inc.	Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
EP1661905B9 (en)	2003-08-28	2012-12-19	IMANISHI, Takeshi	Novel artificial nucleic acids of n-o bond crosslinkage type
EP1791567B1 (en)	2004-08-10	2015-07-29	Alnylam Pharmaceuticals Inc.	Chemically modified oligonucleotides
US20080187508A1 (en)	2004-09-08	2008-08-07	Boys Town National Research Hospital	Treatment of Golmerular Basement Membrane Disease Involving Matrix Metalloproteinase-12
CA2857881A1 (en)	2004-11-12	2006-12-28	Asuragen, Inc.	Methods and compositions involving mirna and mirna inhibitor molecules
WO2006069584A2 (en)	2004-12-29	2006-07-06	Exiqon A/S	NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF microRNAs AND THEIR TARGET mRNAs
US6995235B1 (en)	2005-05-02	2006-02-07	Univation Technologies, Llc	Methods of producing polyolefins and films therefrom
WO2007027894A2 (en) *	2005-08-29	2007-03-08	Isis Pharmaceuticals, Inc.	Antisense compounds having enhanced anti-microrna activity
EP1984499B1 (en)	2006-01-27	2015-05-27	Isis Pharmaceuticals, Inc.	Oligomeric compounds and compositions for the use in modulation of micrornas
JP5342881B2 (ja)	2006-01-27	2013-11-13	アイシスファーマシューティカルズ，インコーポレーテッド	６−修飾された二環式核酸類似体
CA2648132C (en)	2006-04-03	2019-05-28	Santaris Pharma A/S	Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
EP2666859B1 (en) *	2006-04-03	2019-01-02	Roche Innovation Center Copenhagen A/S	Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
EP3192788A1 (en)	2006-10-03	2017-07-19	Arbutus Biopharma Corporation	Lipid containing formulations
EP2489742A1 (de)	2006-10-09	2012-08-22	Julius-Maximilians-Universität Würzburg	MicroRNA (MIRNA) zur Diagnose und Therapie von Herzerkrankungen
WO2008073920A2 (en)	2006-12-08	2008-06-19	Asuragen, Inc.	Mir-21 regulated genes and pathways as targets for therapeutic intervention
WO2008086807A2 (en)	2007-01-19	2008-07-24	Exiqon A/S	Mediated cellular delivery of lna oligonucleotides
EP2170917B1 (en)	2007-05-30	2012-06-27	Isis Pharmaceuticals, Inc.	N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
EP2173760B2 (en)	2007-06-08	2015-11-04	Isis Pharmaceuticals, Inc.	Carbocyclic bicyclic nucleic acid analogs
WO2008151631A2 (en)	2007-06-15	2008-12-18	Exiqon A/S	Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis
CA2692579C (en)	2007-07-05	2016-05-03	Isis Pharmaceuticals, Inc.	6-disubstituted bicyclic nucleic acid analogs
EP2623599B1 (en) *	2007-10-04	2019-01-02	Roche Innovation Center Copenhagen A/S	Micromirs
EP2217248B1 (en)	2007-10-29	2016-11-30	Regulus Therapeutics Inc.	Targeting micrornas for the treatment of liver cancer
US20110257244A1 (en)	2008-01-18	2011-10-20	Alnylam Pharmaceuticals, Inc.	Chemically modified oligonucleotides and small molecules for use in reducing micro rna activity levels and uses thereof
NZ587178A (en)	2008-02-08	2011-11-25	Prosensa Holding Bv	Methods and means for treating dna repeat instability associated genetic disorders
EP2096171A1 (en) *	2008-02-27	2009-09-02	Julius-Maximilians-Universität Würzburg	MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes
EP2268811A1 (en)	2008-03-07	2011-01-05	Santaris Pharma A/S	Pharmaceutical compositions for treatment of microrna related diseases
WO2010099161A1 (en) *	2009-02-26	2010-09-02	The Ohio State University Research Foundation	Micrornas in never-smokers and related materials and methods
CA2765129A1 (en) *	2009-06-08	2010-12-16	Miragen Therapeutics	Chemical modification motifs for mirna inhibitors and mimetics
WO2011126842A2 (en)	2010-03-30	2011-10-13	Regulus Therapeutics Inc.	Targeting micrornas for the treatment of cardiac disorders
EP3211082B1 (en)	2011-04-25	2021-02-17	Sanofi	Microrna compounds and methods for modulating mir-21 activity
WO2013013165A2 (en)	2011-07-21	2013-01-24	The Trustees Of The University Of Pennsylvania	Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus
PE20142404A1 (es)	2012-04-25	2015-02-02	Regulus Therapeutics Inc	Compuestos de microarn y metodos de modulacion de la actividad de mir-21
US9388408B2 (en)	2012-06-21	2016-07-12	MiRagen Therapeutics, Inc.	Oligonucleotide-based inhibitors comprising locked nucleic acid motif
CN104955950B (zh)	2012-09-26	2019-04-26	米尔克斯治疗学公司	具有改善的脱靶特征谱的寡核苷酸
UA116639C2 (uk)	2012-10-09	2018-04-25	Рег'Юлес Терап'Ютікс Інк.	Способи лікування синдрому альпорта

2012
- 2012-04-25 EP EP17153724.4A patent/EP3211082B1/en active Active
- 2012-04-25 PL PL12718549T patent/PL2702155T3/pl unknown
- 2012-04-25 HU HUE12718549A patent/HUE031595T2/en unknown
- 2012-04-25 SG SG2013079454A patent/SG194636A1/en unknown
- 2012-04-25 EP EP12718549.4A patent/EP2702155B9/en active Active
- 2012-04-25 TW TW106131684A patent/TWI698445B/zh active
- 2012-04-25 UA UAA201312414A patent/UA115652C2/uk unknown
- 2012-04-25 PT PT171537244T patent/PT3211082T/pt unknown
- 2012-04-25 MX MX2013012452A patent/MX2013012452A/es unknown
- 2012-04-25 TW TW101114636A patent/TWI607016B/zh active
- 2012-04-25 PT PT127185494T patent/PT2702155T/pt unknown
- 2012-04-25 BR BR112013027187A patent/BR112013027187A2/pt not_active Application Discontinuation
- 2012-04-25 DK DK17153724.4T patent/DK3211082T3/da active
- 2012-04-25 SI SI201231913T patent/SI3211082T1/sl unknown
- 2012-04-25 EP EP21157334.0A patent/EP3933040A1/en not_active Withdrawn
- 2012-04-25 CN CN201280031285.4A patent/CN103620035B/zh active Active
- 2012-04-25 MY MYPI2013003885A patent/MY175336A/en unknown
- 2012-04-25 PH PH1/2013/502199A patent/PH12013502199A1/en unknown
- 2012-04-25 DK DK12718549.4T patent/DK2702155T3/en active
- 2012-04-25 JP JP2014508494A patent/JP6320292B2/ja active Active
- 2012-04-25 KR KR1020137031227A patent/KR102055172B1/ko active Active
- 2012-04-25 ES ES12718549.4T patent/ES2621863T3/es active Active
- 2012-04-25 CA CA3165397A patent/CA3165397A1/en active Pending
- 2012-04-25 HU HUE17153724A patent/HUE054129T2/hu unknown
- 2012-04-25 ES ES17153724T patent/ES2868950T3/es active Active
- 2012-04-25 NZ NZ717921A patent/NZ717921A/en unknown
- 2012-04-25 US US14/111,976 patent/US9181547B2/en active Active
- 2012-04-25 CN CN202110383567.1A patent/CN113249381A/zh active Pending
- 2012-04-25 EA EA201391492A patent/EA025894B1/ru not_active IP Right Cessation
- 2012-04-25 HR HRP20170557TT patent/HRP20170557T2/hr unknown
- 2012-04-25 SI SI201230924A patent/SI2702155T1/sl unknown
- 2012-04-25 AU AU2012249851A patent/AU2012249851B2/en active Active
- 2012-04-25 MY MYPI2017000706A patent/MY187685A/en unknown
- 2012-04-25 KR KR1020197015054A patent/KR20190063482A/ko not_active Ceased
- 2012-04-25 PL PL17153724T patent/PL3211082T3/pl unknown
- 2012-04-25 RS RS20210552A patent/RS61775B1/sr unknown
- 2012-04-25 LT LTEP17153724.4T patent/LT3211082T/lt unknown
- 2012-04-25 CN CN202110384864.8A patent/CN113151272A/zh active Pending
- 2012-04-25 CA CA2833615A patent/CA2833615C/en active Active
- 2012-04-25 WO PCT/US2012/034880 patent/WO2012148952A1/en not_active Ceased
- 2012-04-25 MX MX2019003090A patent/MX393138B/es unknown
- 2012-04-25 US US13/455,337 patent/US20120270928A1/en active Pending
- 2012-04-25 LT LTEP12718549.4T patent/LT2702155T/lt unknown
2013
- 2013-10-23 MX MX2022000212A patent/MX2022000212A/es unknown
- 2013-10-23 IL IL229032A patent/IL229032B/en active IP Right Grant
- 2013-10-23 MX MX2019003089A patent/MX2019003089A/es unknown
- 2013-10-23 MX MX2022006595A patent/MX2022006595A/es unknown
- 2013-10-25 CL CL2013003105A patent/CL2013003105A1/es unknown
- 2013-10-30 CO CO13257480A patent/CO6821889A2/es unknown
2014
- 2014-07-28 US US14/444,406 patent/US8912161B2/en active Active
2015
- 2015-10-14 US US14/883,055 patent/US9790496B2/en active Active
2017
- 2017-04-25 CY CY20171100460T patent/CY1120304T1/el unknown
- 2017-08-29 AU AU2017219156A patent/AU2017219156B2/en active Active
- 2017-09-14 US US15/704,749 patent/US20180155719A1/en not_active Abandoned
2018
- 2018-04-02 JP JP2018070694A patent/JP2018121646A/ja active Pending
2019
- 2019-05-08 IL IL266529A patent/IL266529A/en unknown
2020
- 2020-01-24 US US16/751,402 patent/US20200291400A1/en not_active Abandoned
- 2020-02-26 AU AU2020201403A patent/AU2020201403A1/en not_active Abandoned
- 2020-03-18 IL IL273381A patent/IL273381A/en unknown
2021
- 2021-04-19 HR HRP20210616TT patent/HRP20210616T1/hr unknown
- 2021-08-18 US US17/405,482 patent/US12331294B2/en active Active
2022
- 2022-05-06 AU AU2022203067A patent/AU2022203067A1/en not_active Abandoned

Also Published As

Publication number	Publication date
HRP20210616T1 (hr)	2021-05-28
US9790496B2 (en)	2017-10-17
IL266529A (en)	2019-07-31
NZ616748A (en)	2016-03-31
HRP20170557T1 (hr)	2017-06-16
ES2621863T9 (es)	2020-02-13
WO2012148952A1 (en)	2012-11-01
JP2014518619A (ja)	2014-08-07
JP6320292B2 (ja)	2018-05-09
CA2833615A1 (en)	2012-11-01
EP2702155B1 (en)	2017-02-01
CN113151272A (zh)	2021-07-23
MX2022006595A (es)	2022-07-01
EP3211082A1 (en)	2017-08-30
AU2012249851B2 (en)	2017-06-08
AU2012249851A8 (en)	2013-11-14
TWI607016B (zh)	2017-12-01
PT2702155T (pt)	2017-04-03
CA2833615C (en)	2022-08-30
US20200291400A1 (en)	2020-09-17
JP2018121646A (ja)	2018-08-09
MX2019003090A (es)	2019-07-18
PH12013502199A1 (en)	2014-01-27
CN113249381A (zh)	2021-08-13
RS61775B1 (sr)	2021-05-31
ES2621863T3 (es)	2017-07-05
EP3211082B1 (en)	2021-02-17
SI3211082T1 (sl)	2021-08-31
US12331294B2 (en)	2025-06-17
LT3211082T (lt)	2021-05-10
HK1243130A1 (en)	2018-07-06
CN103620035A (zh)	2014-03-05
CO6821889A2 (es)	2013-12-31
US20220098583A1 (en)	2022-03-31
DK2702155T3 (en)	2017-05-01
EP2702155B9 (en)	2020-01-01
EP3933040A1 (en)	2022-01-05
PL2702155T3 (pl)	2017-09-29
MX393138B (es)	2025-03-24
BR112013027187A2 (pt)	2017-06-06
HUE054129T2 (hu)	2021-08-30
MX2019003089A (es)	2019-07-18
US20120270928A1 (en)	2012-10-25
DK3211082T3 (da)	2021-05-10
KR20190063482A (ko)	2019-06-07
TWI698445B (zh)	2020-07-11
IL229032A0 (en)	2013-12-31
ES2868950T3 (es)	2021-10-22
HRP20170557T2 (hr)	2020-02-21
KR102055172B1 (ko)	2020-01-23
US8912161B2 (en)	2014-12-16
PT3211082T (pt)	2021-04-28
TW201300404A (zh)	2013-01-01
EP2702155A1 (en)	2014-03-05
MY175336A (en)	2020-06-19
CY1120304T1 (el)	2019-07-10
US20160138016A1 (en)	2016-05-19
US9181547B2 (en)	2015-11-10
US20140107183A1 (en)	2014-04-17
NZ717921A (en)	2017-09-29
CN103620035B (zh)	2021-04-23
US20180155719A1 (en)	2018-06-07
KR20140033062A (ko)	2014-03-17
CL2013003105A1 (es)	2014-08-01
MX2013012452A (es)	2014-11-21
TW201811812A (zh)	2018-04-01
UA115652C2 (uk)	2017-12-11
AU2012249851A1 (en)	2013-10-31
MX2022000212A (es)	2022-04-01
AU2020201403A1 (en)	2020-03-12
EA025894B1 (ru)	2017-02-28
EA201391492A1 (ru)	2014-04-30
SG194636A1 (en)	2013-12-30
SI2702155T1 (sl)	2017-07-31
AU2017219156B2 (en)	2020-01-02
CA3165397A1 (en)	2012-11-01
US20140329887A1 (en)	2014-11-06
AU2017219156A1 (en)	2017-09-21
HUE031595T2 (en)	2017-07-28
MY187685A (en)	2021-10-11
IL273381A (en)	2020-05-31
AU2022203067A1 (en)	2022-05-26
IL229032B (en)	2021-01-31
PL3211082T3 (pl)	2021-08-02

Publication	Publication Date	Title
IL273381A (en)	2020-05-31	MicroRNA compounds and methods to modulate mir-21 activity
ZA201407228B (en)	2017-05-31	Microrna compounds and methods for modulating mir-21 activity
GB2528399B (en)	2016-03-02	Catalyst and method for its preparation
PT3636274T (pt)	2024-10-17	Composições para modular a atividade das citocinas gama-c
IL228546A0 (en)	2013-12-31	fermentation process
GB201112231D0 (en)	2011-08-31	Micro-organism
IL229446A0 (en)	2014-01-30	Rolled collagen carrier
SG11201403280PA (en)	2014-07-30	Bioreactor
EP2864469A4 (en)	2016-05-18	BIOREACTOR CARTRIDGE AND SYSTEM
IL228700A0 (en)	2013-12-31	A method for modulating cytokine activity
GB201108165D0 (en)	2011-06-29	Bioreactor chamber and method
GB201109849D0 (en)	2011-07-27	Modulation
AU2011011V (en)	2012-09-04	FFV1 Ficus obliqua
GB201111898D0 (en)	2011-08-24	Bioreactor chamber and method
GB201122254D0 (en)	2012-02-01	Bioreactor chamber and method
GB201105578D0 (en)	2011-05-18	Osteoclast activity
GB201105580D0 (en)	2011-05-18	Osteoclast activity
GB201105579D0 (en)	2011-05-18	Osteoclast activity